Flotetuzumab
- Generic Name
- Flotetuzumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1664355-28-5
- Unique Ingredient Identifier
- 0AHT0IC02G
- Background
Flotetuzumab is under investigation in clinical trial NCT02152956 (Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS).
- Associated Conditions
- -
- Associated Therapies
- -
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
Phase 1
Active, not recruiting
- Conditions
- Recurrent Acute LeukemiaRecurrent B Acute Lymphoblastic LeukemiaRecurrent Blastic Plasmacytoid Dendritic Cell NeoplasmRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRefractory Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRefractory Hairy Cell LeukemiaRefractory Hematologic MalignancyRefractory Hodgkin LymphomaRefractory T Acute Lymphoblastic LeukemiaSystemic Mastocytosis
- Interventions
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 13
- Registration Number
- NCT04681105
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath